From Raynaud Phenomenon to Systemic Sclerosis in COVID-19: A Case Report.

Adv Skin Wound Care

In the Rheumatology Unit, University of Modena and Reggio Emilia Medical School, Azienda Ospedaliero-Universitaria, Policlinico di Modena, Italy, Dilia Giuggioli, MD, PhD, is Associate Professor; Amelia Spinella, MD, PhD, is Medical Assistant; Marco de Pinto, MD, is Resident; Mascia Maria Teresa, MD, is Associate Professor; and Carlo Salvarani, MD, is Full Professor. The authors have disclosed no financial relationships related to this article. Submitted December 21, 2020; accepted in revised form March 15, 2021; published online ahead of print October 6, 2021.

Published: February 2022

In 2019, the novel SARS-CoV-2 infection emerged, causing the disease called COVID-19, which primarily affects the respiratory tract and lung at alveolar and interstitial levels. Systemic sclerosis (SSc) is an autoimmune connective disease characterized by vascular abnormalities and diffuse and progressive fibrosis of the skin and internal organs. Raynaud phenomenon (RP) occurs in virtually all patients affected by SSc and, in most cases, is an onset symptom of the disease; that is, RP may appear several years before overt illness. Although the exact pathophysiologic pathways leading to RP and SSc are still unknown, several infectious agents, especially viruses, have been suggested as possible triggering factors. Here, the authors describe the first case of RP secondary to SSc following SARS-CoV-2 infection.

Download full-text PDF

Source
http://dx.doi.org/10.1097/01.ASW.0000795240.63966.53DOI Listing

Publication Analysis

Top Keywords

raynaud phenomenon
8
systemic sclerosis
8
sars-cov-2 infection
8
phenomenon systemic
4
sclerosis covid-19
4
covid-19 case
4
case report
4
report 2019
4
2019 novel
4
novel sars-cov-2
4

Similar Publications

Iloprost is a synthetic long-acting prostacyclin-analog drug used to treat various vascular diseases. The Federal Drug Administration approved the drug in 2004 for pulmonary arterial hypertension, and it has since been shown to be helpful in other vascular conditions such as scleroderma and Raynaud phenomenon. The Federal Drug Administration has now approved the use of iloprost for severe frostbite.

View Article and Find Full Text PDF

Systemic sclerosis-associated Raynaud phenomenon (SSc-RP) confers poor outcomes, including ulceration, gangrene, autoamputation, and hand disability. Prostaglandin analogues (PG) are a group of prostacyclin-derived drugs with properties that may address underlying complex mechanisms of SSc-RP. This systematic review and meta-analysis evaluated the efficacy and tolerability of PGs in SSc-RP.

View Article and Find Full Text PDF

It is well established that host immunity plays a critical role in defending against colorectal cancer (CRC) progression. Connective tissue disease (CTD) encompasses a group of heterogeneous, immune-mediated disorders that present with diverse and often non-specific initial symptoms. Raynaud's phenomenon is a common feature, complicating early diagnosis.

View Article and Find Full Text PDF

Primary Raynaud's phenomenon (RP) is a common and self-limiting condition, which is not secondary to any other disease process. In contrast, secondary RP has an underlying etiology. Several conditions can lead to secondary RP, which creates a challenging landscape for clinicians.

View Article and Find Full Text PDF

Objective: The Very Early Diagnosis of Systemic Sclerosis (VEDOSS) EUSTAR study showed that, despite not showing any clinical sign of disease, patients with Raynaud's and antinuclear antibodies and/or capillaroscopy abnormalities often progress to systemic sclerosis (SSc) within 5 years. We aimed to determine whether VEDOSS biosamples show biological SSc activity pre-clinically.

Methods: Skin biopsies were histologically analysed.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!